Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | Unknown | — |
The patient received two doses of Rabavert and did not come back for the third; Case reference number US-BN-2025-000388 is a spontaneous case report initially received from a nurse via MisCommunication (reference number: USBAV25-0789) on 08-Apr-2025 and concerns a female patient of unspecified age. The patient's relevant medical history and concomitant medications were not provided. On an unspecified date, the patient took first dose of Rabavert vaccine along with prefilled syringe, needle for injection and injection for reconstitution (batch number: unknown) at an unknown dose, route and site of administration for unknown indication. On an unspecified date, the patient took second dose of Rabavert vaccine along with prefilled syringe, needle for injection and injection for reconstitution (batch number: unknown) at an unknown dose, route and site of administration. As reported, an animal control person that had two doses but didn't come back for the third (explicitly coded as 'incomplete course of vaccination'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Rabavert vaccine. No further information was provided.; Reporter's Comments: A female patient of unspecified age had two doses but didn't come back for the third which is considered as incomplete course of vaccination. Incomplete course of vaccination is considered listed per company convention. At the time of the initial report, it was unknown if the patient experienced any adverse events due to Rabavert vaccine. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A female patient of unspecified age had two doses but didn't come back for the third which is considered as incomplete course of vaccination. Incomplete course of vaccination is considered listed per company convention. At the time of the initial report, it was unknown if the patient experienced any adverse events due to Rabavert vaccine. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None.